临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2014年
14期
1150-1152
,共3页
吴强%王楚林%林宇鹏%陈晓英
吳彊%王楚林%林宇鵬%陳曉英
오강%왕초림%림우붕%진효영
急性冠脉综合征%无复流现象%经皮冠状动脉介入术%替罗非班%维拉帕米
急性冠脈綜閤徵%無複流現象%經皮冠狀動脈介入術%替囉非班%維拉帕米
급성관맥종합정%무복류현상%경피관상동맥개입술%체라비반%유랍파미
Acute coronary syndrome%No - flow phenomenon%Percutaneous coronary intervention%Tirofiban%Verapamil
目的:对比观察替罗非班与维拉帕米治疗急性冠脉综合征(ACS)介入术后无复流的临床疗效。方法选取经皮冠状动脉介入术后无复流 ACS 患者60例随机分为替罗非班治疗组和维拉帕米治疗组。经冠状动脉给药后48 h,观察并记录两组患者 TIMI 血流分级及心电图变化;术后2周,观察并记录心源性猝死、再发心绞痛、新发心肌梗死等心脏不良事件的发生率。结果替罗非班组 TIMI 血流0级、1级发生率显著低于维拉帕米组,TIMI 血流2级、3级发生率显著高于维拉帕米组,两组比较差异有显著性( P ﹤0.05);替罗非班组心电图改善明显,与维拉帕米组比较差异有显著性( P ﹤0.05);术后2周替罗非班组不良心脏事件发生率显著低于维拉帕米组( P ﹤0.01)。结论替罗非班治疗急性冠脉综合征介入术后无复流现象安全有效,值得临床推广使用。
目的:對比觀察替囉非班與維拉帕米治療急性冠脈綜閤徵(ACS)介入術後無複流的臨床療效。方法選取經皮冠狀動脈介入術後無複流 ACS 患者60例隨機分為替囉非班治療組和維拉帕米治療組。經冠狀動脈給藥後48 h,觀察併記錄兩組患者 TIMI 血流分級及心電圖變化;術後2週,觀察併記錄心源性猝死、再髮心絞痛、新髮心肌梗死等心髒不良事件的髮生率。結果替囉非班組 TIMI 血流0級、1級髮生率顯著低于維拉帕米組,TIMI 血流2級、3級髮生率顯著高于維拉帕米組,兩組比較差異有顯著性( P ﹤0.05);替囉非班組心電圖改善明顯,與維拉帕米組比較差異有顯著性( P ﹤0.05);術後2週替囉非班組不良心髒事件髮生率顯著低于維拉帕米組( P ﹤0.01)。結論替囉非班治療急性冠脈綜閤徵介入術後無複流現象安全有效,值得臨床推廣使用。
목적:대비관찰체라비반여유랍파미치료급성관맥종합정(ACS)개입술후무복류적림상료효。방법선취경피관상동맥개입술후무복류 ACS 환자60례수궤분위체라비반치료조화유랍파미치료조。경관상동맥급약후48 h,관찰병기록량조환자 TIMI 혈류분급급심전도변화;술후2주,관찰병기록심원성졸사、재발심교통、신발심기경사등심장불량사건적발생솔。결과체라비반조 TIMI 혈류0급、1급발생솔현저저우유랍파미조,TIMI 혈류2급、3급발생솔현저고우유랍파미조,량조비교차이유현저성( P ﹤0.05);체라비반조심전도개선명현,여유랍파미조비교차이유현저성( P ﹤0.05);술후2주체라비반조불양심장사건발생솔현저저우유랍파미조( P ﹤0.01)。결론체라비반치료급성관맥종합정개입술후무복류현상안전유효,치득림상추엄사용。
Objective To observe the clinical effect of tirofiban and verapamil in acute coronary syndrome(ACS)patients with no - reflow phenomenon after percutaneous coronary intervention(PCI). Methods Sixty ACS patients who had no - reflow phenomenon during PCI were di-vided into verapamil treatment group and tirofiban treatment group. Two groups of patients were observed and recorded TIMI flow grade and ECG changes and the sudden cardiac death,recurrent angina,the incidence of new - onset myocardial infarction and other cardiac adverse events after two weeks. Results In tirofiban group the occurrence rates of TIMI grades 0 and 1 were significantly lower than those in verapamil group but the occurrence rates of TIMI grades 2 and 3 were significantly higher than those in verapamil group( P ﹤ 0. 05). The changes of ECG of tirofiban treat-ment group were significantly better than verapamil treatment group( P ﹤ 0. 05). Within 2 weeks after PCI,the major adverse cardiac events were less in tirofiban treatment group than those in verapamil treatment group( P ﹤ 0. 01). Conclusion The treatment with tirofiban through coronary artery can effectively relieve no - reflow phenomenon after PCI.